Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Logotype for Insulet Corporation

Insulet (PODD) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary

Event summary combining transcript, slides, and related documents.

Logotype for Insulet Corporation

Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary

24 Sep, 2026

Business performance and market opportunity

  • Achieved strong Q2 results with 23% organic growth, 20% U.S. Omnipod growth, 33% international Omnipod growth, and 140 basis points of operating margin expansion.

  • Markets for automated insulin delivery (AID) remain large and under-penetrated, with only 5% of insulin-intensive type 2 diabetes patients in the U.S. using AID.

  • International business grew over 30% YoY, with 75% of the OUS DASH base converted to Omnipod 5 and new launches in Spain, Germany, and Canada.

  • High retention rates after 90 days for both type 1 and type 2 customers support a durable business model.

  • Type 2 IIT penetration is targeted to reach 10%-15% by 2028, with potential to go significantly higher, inspired by CGM adoption rates.

Strategic initiatives and corrective actions

  • Four key actions to improve type 2 retention: revamping the sampling program, adjusting field incentives, scaling support teams, and accelerating Omnipod Discover rollout.

  • Sampling workflow improvements ensure customers are supported and ready for long-term use.

  • Field incentives now emphasize durable starts and early customer success, with best practices shared across teams.

  • Customer service and clinical retention specialists provide targeted support during the first 90 days, proven effective in pilot programs.

  • Omnipod Discover, a digital health platform, will be fully launched by year-end to enhance engagement and retention.

Innovation pipeline and product development

  • Recent launches include a second-generation algorithm for tighter glycemic control and FreeStyle Libre 3 Plus integration.

  • Omnipod 6, launching in 2027, will offer a new algorithm, improved wear flexibility, and updatable pods for faster innovation.

  • Type 2 fully closed loop system, in pivotal study, targets a disruptively simple user experience and broader primary care adoption by 2028.

  • Continued algorithm updates and hardware innovations are planned through 2029 and beyond.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more